<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02457910</url>
  </required_header>
  <id_info>
    <org_study_id>VICC BRE 1374</org_study_id>
    <secondary_id>NCI-2015-00795</secondary_id>
    <secondary_id>GO28972</secondary_id>
    <secondary_id>TBCRC 032</secondary_id>
    <secondary_id>VICC BRE 1374</secondary_id>
    <secondary_id>P30CA068485</secondary_id>
    <nct_id>NCT02457910</nct_id>
  </id_info>
  <brief_title>Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer</brief_title>
  <official_title>A Phase Ib/II Trial of Taselisib (GDC-0032), a PI3K Inhibitor, in Combination With Enzalutamide in Patients With Androgen Receptor Positive Triple Negative Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt-Ingram Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Translational Breast Cancer Research Consortium</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Conquer Cancer Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt-Ingram Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This partially randomized phase Ib/II trial studies the side effects and best dose of
      taselisib when given together with enzalutamide and to see how well they work in treating
      patients with androgen receptor positive triple-negative breast cancer that has spread to
      other places in the body. Taselisib is a PI3K inhibitor. The PI3K pathway is involved is
      cancer growth. Androgen may cause the growth of tumor cells. Enzalutamide may stop the growth
      of tumor cells by blocking the androgen receptor from working. Giving taselisib with
      enzalutamide may be a better treatment for patients with breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the safety and tolerability of taselisib given in combination with
      enzalutamide: Assessment of dose limiting toxicities (DLTs) during the first 4 weeks of
      treatment (cycle 1). (Phase Ib) II. To determine the safety and tolerability of taselisib
      given in combination with enzalutamide: Determination of the maximally tolerated dose (MTD)
      of taselisib given in combination with enzalutamide. (Phase Ib) III. To evaluate the
      efficacy, as measured by clinical benefit rate (CBR), of enzalutamide + taselisib in patients
      with androgen receptor positive (AR+) triple negative (TN) metastatic breast cancer (MBC).
      (Phase II)

      SECONDARY OBJECTIVES:

      I. To determine the progression free survival (PFS) of enzalutamide + taselisib in patients
      with AR+ TN MBC.

      II. To assess the pharmacokinetics (PKs) of taselisib and enzalutamide in patients with AR+
      TN MBC.

      TERTIARY OBJECTIVES:

      I. To explore predictors of biomarker response and mechanisms of resistance based on
      exploratory analysis of tumor tissue obtained through biopsies.

      II. Levels of phosphatase and tensin homolog (PTEN) expression by immunohistochemistry (IHC)
      and quantitative real-time polymerase chain reaction (qPCR).

      III. Presence of mutations in the phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic
      subunit alpha (PIK3CA) gene.

      IV. Human epidermal growth factor receptor 2 (HER2) (IHC, fluorescence in situ hybridization
      [FISH]) and estrogen receptor (ER)/progesterone receptor (PR) levels (IHC) in tumor biopsy
      from a metastatic site.

      V. Levels of mitogen-activated protein kinase kinase (MEK) activity measured by
      phosphorylated extracellular-signal-regulated kinases (p-ERK1/2) (IHC) and phosphorylated
      p-ribosomal protein S6 (S6) (S235/236 and S240/244) at baseline and upon progression of
      disease.

      VI. Levels of phosphorylated v-akt murine thymoma viral oncogene homolog 1 (p-AKT) (IHC) at
      baseline and upon progression of disease.

      VII. Gene expression profiling to assign a triple negative subtype. VIII. Whole exome
      deoxyribonucleic acid (DNA)-sequencing (seq) on DNA isolated at baseline and upon
      progression.

      IX. Plasma for circulating tumor DNA (ctDNA) analysis to assess PIK3CA mutation status in
      response and resistance.

      X. To assess the predictive effects of PIK3CA mutations and PTEN loss on PFS and CBR.

      XI. To evaluate the ability of multi-parametric magnetic resonance imaging (MRI) performed
      early in therapy to predict both biological and clinical response.

      OUTLINE: This is a phase Ib, dose-escalation study of taselisib followed by a randomized
      phase II study.

      PHASE IB: Patients receive taselisib orally (PO) once daily (QD) on days 1-28 and
      enzalutamide PO QD on days 9-28 of course 1 and days 1-28 of subsequent courses. Courses
      repeat every 28 days in the absence of disease progression or unacceptable toxicity.

      PHASE II: Patients are randomized to 1 of 2 treatment arms.

      ARM I: Patients receive taselisib PO QD and enzalutamide as in Phase Ib. Courses repeat every
      28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing
      unacceptable toxicity due to enzalutamide may continue to receive taselisib.

      ARM II: Patients receive enzalutamide PO QD on days 1-28. Courses repeat every 28 days in the
      absence of disease progression or unacceptable toxicity. Upon disease progression, patients
      may crossover to Arm I.

      After completion of study treatment, patients are followed up for 30 days and then every 3
      months for 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Actual">December 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Benefit Rate (CBR) - Phase II</measure>
    <time_frame>At 16 weeks</time_frame>
    <description>CBR is defined as the proportion of patients with a best response of complete response (CR), partial response (PR), or (SD) stable disease per RECIST criteria 1.1. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt;10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions. PD: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition, the sum must also demonstrate an absolute increase of at least 5 mm. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of diameters while on study. It is calculated as the mean of binomial distribution.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) of Taselisib Combined With 160mg Enzalutamide - Phase I</measure>
    <time_frame>4 weeks</time_frame>
    <description>defined as the highest dose tested in which a dose limiting toxicity is experienced by 0 out of 3 or 1 out of 6 patients among the dose levels. Dose limiting toxicity will be graded according to the National Cancer Institute CTCAE version 4.0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Progression-Free Survival (PFS) of Patients Treated With Enzalutamide and Taselisib</measure>
    <time_frame>Time from course 1, day 1 until objective tumor progression, assessed up to 3 years</time_frame>
    <description>The PFS time is defined as the time from treatment start to progression or death (whichever comes first), and those alive without progression were censored at the last date of follow up. PFS will be estimated using the Kaplan-Meier method. The median with 95% confidence intervals will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Profile</measure>
    <time_frame>Approximately 4 months</time_frame>
    <description>Pharmacokinetic sampling will occur in the phase Ib portion and in 10 patients in the phase II portion</description>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Estrogen Receptor Negative</condition>
  <condition>Estrogen Receptor Positive</condition>
  <condition>HER2/Neu Negative</condition>
  <condition>Progesterone Receptor Negative</condition>
  <condition>Progesterone Receptor Positive</condition>
  <condition>Stage IV Breast Cancer</condition>
  <condition>Triple-Negative Breast Carcinoma</condition>
  <arm_group>
    <arm_group_label>Taselisib 2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive taselisib PO QD on days 1-28 and enzalutamide PO QD on days 9-28 of course 1 and days 1-28 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing unacceptable toxicity due to enzalutamide may continue to receive taselisib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enzalutamide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive enzalutamide PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Upon disease progression, patients may crossover to receive Enzalutamide + Taselisib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Taselisib 4 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive taselisib PO QD on days 1-28 and enzalutamide PO QD on days 9-28 of course 1 and days 1-28 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing unacceptable toxicity due to enzalutamide may continue to receive taselisib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Taselisib 6 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive taselisib PO QD on days 1-28 and enzalutamide PO QD on days 9-28 of course 1 and days 1-28 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing unacceptable toxicity due to enzalutamide may continue to receive taselisib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Taselisib 8 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive taselisib PO QD on days 1-28 and enzalutamide PO QD on days 9-28 of course 1 and days 1-28 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing unacceptable toxicity due to enzalutamide may continue to receive taselisib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enzalutamide + Taselisib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive enzalutamide PO QD starting on day 1 of cycle 1, and will receive Taselisib PO QD starting on day 1 of cycle 2. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cross-Over</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Upon progression of disease, patients on the enzalutamide only arm will be allowed to crossover to enzalutamide + taselisib (must begin no later than 21 days after the clinic visit at which disease progression is determined) Enzalutamide and Taselisib will be taken PO QD</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Cross-Over</arm_group_label>
    <arm_group_label>Enzalutamide</arm_group_label>
    <arm_group_label>Enzalutamide + Taselisib</arm_group_label>
    <arm_group_label>Taselisib 2 mg</arm_group_label>
    <arm_group_label>Taselisib 4 mg</arm_group_label>
    <arm_group_label>Taselisib 6 mg</arm_group_label>
    <arm_group_label>Taselisib 8 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enzalutamide</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Cross-Over</arm_group_label>
    <arm_group_label>Enzalutamide</arm_group_label>
    <arm_group_label>Enzalutamide + Taselisib</arm_group_label>
    <arm_group_label>Taselisib 2 mg</arm_group_label>
    <arm_group_label>Taselisib 4 mg</arm_group_label>
    <arm_group_label>Taselisib 6 mg</arm_group_label>
    <arm_group_label>Taselisib 8 mg</arm_group_label>
    <other_name>MDV3100</other_name>
    <other_name>Xtandi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacological Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Cross-Over</arm_group_label>
    <arm_group_label>Enzalutamide</arm_group_label>
    <arm_group_label>Enzalutamide + Taselisib</arm_group_label>
    <arm_group_label>Taselisib 2 mg</arm_group_label>
    <arm_group_label>Taselisib 4 mg</arm_group_label>
    <arm_group_label>Taselisib 6 mg</arm_group_label>
    <arm_group_label>Taselisib 8 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Taselisib</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Cross-Over</arm_group_label>
    <arm_group_label>Enzalutamide + Taselisib</arm_group_label>
    <arm_group_label>Taselisib 2 mg</arm_group_label>
    <arm_group_label>Taselisib 4 mg</arm_group_label>
    <arm_group_label>Taselisib 6 mg</arm_group_label>
    <arm_group_label>Taselisib 8 mg</arm_group_label>
    <other_name>GDC-0032</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must provide informed written consent

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1

          -  Clinical stage IV invasive mammary carcinoma

          -  For phase 1b: HER2 negative, as defined for phase II; any ER/PR (negative or positive)
             can be enrolled in the phase 1b portion

          -  For phase II: ER negative (defined as expression of ER in =&lt; 1% cells), PR negative
             (defined as expression of PR in =&lt; 1% cells), HER2 negative (acceptable methods of
             HER2 analysis include IHC [0, 1+], fluorescence in situ hybridization [FISH] with
             HER2/centromere on chromosome 17 [CEN17] ratio &lt; 2, and/or chromogenic in situ
             hybridization [CISH] with HER2/CEN-17 ratio &lt; 2), as previously documented by
             histological analysis

          -  Androgen receptor positivity, defined as &gt;= 10% of tumor cell nuclei with
             immunoreactivity for AR on central review at Vanderbilt

          -  Measurable or bone-only evaluable disease; measurable disease is defined as at least
             one lesion that can be accurately measured in at least one dimension by Response
             Evaluation Criteria in Solid Tumors (RECIST) criteria 1.1, with radiologic scans
             within 21 days of day 1, cycle 1

          -  Any number of prior therapies as long as patients have adequate performance status and
             meet all other eligibility criteria

          -  Prior treatment with anti-androgens other than enzalutamide is acceptable

          -  Phase 1b only: Formalin-fixed paraffin embedded blocks (FFPB) or fresh frozen tissue
             from the original diagnosis or the metastatic setting should be located; tissue must
             be submitted with 3 weeks of study initiation

          -  Phase II only: Biopsy of a metastatic lesion in patients with reasonably accessible
             metastatic lesions (chest wall, skin, subcutaneous tissue, lymph nodes, skin, breast,
             bones, lung, and liver metastases); if a reasonably accessible metastatic lesion is
             not available, the patient may go on study provided that archived tissue is available;
             however, if a reasonably accessible site is available for biopsy, the patient must
             agree to biopsy; any patients not undergoing biopsy must be approved for study
             enrollment by the Protocol Chair; biopsies may be done with local anesthesia or
             intravenous conscious sedation, according to institutional guidelines; if a biopsy
             requires general anesthesia, then it is only allowed if acquisition of tissue is
             clinically indicated, and excess tissue may be collected for research purposes;
             patients without sites available for biopsy must have available tissue (archived
             formalin-fixed paraffin embedded blocks [FFPB] or fresh frozen tissue from original
             diagnosis or metastatic setting) for correlative studies; tissue needs to be located
             and available at the time of registration (tissue needs to be submitted within 3 weeks
             of study initiation)

          -  Patients must have adequate hematologic, hepatic, and renal function. All tests must
             be obtained within 28 days of starting treatment. Labs are to be repeated on cycle 1,
             day 1 and must still meet eligibility. These include:

          -  Absolute neutrophil count (ANC) &gt;= 1500/mm^3

          -  Platelet count &gt;= 75,000/mm^3

          -  Hemoglobin (HgB) &gt;= 9 g/dL

          -  Creatinine =&lt; 1.5 X upper limits of normal (ULN)

          -  international normalized ratio (INR) â‰¤2

          -  Total serum bilirubin =&lt; 1.5 x ULN (in patients with known Gilbert syndrome, a total
             bilirubin =&lt; 3.0 x ULN, with direct bilirubin =&lt; 1.5 x ULN)

          -  Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =&lt; 3 x ULN (or =&lt;
             5.0 x ULN if hepatic metastases are present)

          -  For patients without known type II diabetes, the following is required at screening:

               -  Fasting plasma glucose =&lt; 160 mg/dL (7.49 mmol/L) and glycosylated hemoglobin
                  (HbA1c) &lt; 7.5 % or International Federation of Clinical Chemistry (IFCC) &lt; 53
                  mmol/mol

          -  For patients with type II diabetes receiving only oral anti-hyperglycemic therapy
             (patients receiving insulin are not eligible), the following are required at
             screening:

               -  HbA1c &lt; 8.5 % or IFCC &lt; 69.4 mmol/mol

               -  Stable regimen of oral anti-hyperglycemic therapy without insulin usage for at
                  least 3 weeks prior to first study treatment

               -  Fasting plasma glucose levels =&lt; 160 mg/dL (8.88 mmol/L) and no hypoglycemia
                  (blood sugar [BS] &lt; 60) during home monitoring for at least 1 week prior to study
                  entry

          -  Patients must be able to swallow and retain oral medication

          -  For patients who are not postmenopausal or surgically sterile (absence of ovaries
             and/or uterus), agreement to remain abstinent or to use two adequate methods of
             contraception (e.g., condoms, diaphragm, vasectomy/vasectomized partner, tubal
             ligation), during the treatment period and for at least 30 days after the last dose of
             study treatment or 3 months after discontinuation of taselisib and/or enzalutamide,
             whichever is longer; hormone based oral contraceptives are not allowed on study;
             postmenopausal is defined as:

               -  Age &gt;= 60 years

               -  Age =&lt; 60 years and amenorrheic for 12 months in the absence of chemotherapy,
                  tamoxifen, toremifene, or ovarian suppression; or follicle stimulating hormone
                  and estradiol in the postmenopausal range

          -  Patients may have received radiation therapy to painful bone metastases or areas of
             impending bone fracture as long as radiation therapy is completed &gt;= 2 weeks prior to
             day 1 of cycle 1 of treatment; patients who have received prior radiotherapy must have
             recovered from toxicity (=&lt; grade 1) induced by this treatment; baseline radiologic
             scans must be obtained after completion of radiation

          -  Patients must complete all screening assessments

        Exclusion Criteria:

          -  Any kind of malabsorption syndrome significantly affecting gastrointestinal function,
             including history of Crohn's disease or inflammatory bowel disease

          -  Concurrent anti-cancer therapy (chemotherapy, radiation therapy, surgery,
             immunotherapy, hormonal therapy, biologic therapy) other than the ones specified in
             the protocol; patients must have discontinued the above cancer therapies for 1 week
             prior to the first dose of study medication, as well as recovered to baseline from
             toxicity induced by previous treatments; any investigational drugs should be
             discontinued 2 weeks prior to the first dose of study medication and radiotherapy must
             have been completed &gt;= 2 weeks prior to initiation of study drug (cycle 1, day 1)

          -  Prior use of PI3K or Akt inhibitors in the metastatic setting for the treatment of
             cancer; these include, but are not limited to: taselisib, GDC-0941, GDC-0980, BEZ235,
             BKM120, LY294002, PIK-75, TGX-221, XL147, XL765, SF1126, PX-866, D-87503, D-106669,
             GSK615, CAL101; patients who have received PI3K/Akt inhibitors previously for &lt; 4
             weeks will be eligible

          -  Prior treatment with enzalutamide

          -  Current or previously treated brain metastasis or active leptomeningeal disease; head
             imaging is required during screening in all patients to exclude the presence of
             central nervous system (CNS) metastatic disease

          -  History of seizure or any condition that may predispose to seizure; history of loss of
             consciousness or transient ischemic attack within 12 months before day 1

          -  Pregnant or lactating women

          -  Insulin-dependent diabetes; patients with type II diabetes must meet the inclusion
             criteria outlined above

          -  Uncontrolled intercurrent illness including, but not limited to:

               -  Ongoing or active infection requiring parenteral antibiotics

               -  Impairment of lung function (chronic obstructive pulmonary disease [COPD] &gt; grade
                  2, lung conditions requiring oxygen therapy) or current dyspnea at rest

               -  Symptomatic congestive heart failure (class III or IV of the New York Heart
                  Association classification for heart disease)

               -  Known left ventricular ejection fraction (LVEF) &lt; 50%

               -  Unstable angina pectoris, angioplasty, stenting, or myocardial infarction within
                  6 months

               -  Uncontrolled hypertension (systolic blood pressure &gt; 160 mm Hg or diastolic blood
                  pressure &gt; 100 mm Hg, found on two consecutive measurements separated by a 1 or
                  2-week period despite adequate medical support)

               -  Clinically significant cardiac arrhythmia (multifocal premature ventricular
                  contractions, bigeminy, trigeminy, ventricular tachycardia that is symptomatic or
                  requires treatment [National Cancer Institute-Common Terminology Criteria for
                  Adverse Events, version 4.0, grade 3])

               -  Corrected QT using the Fridericia correction formula (QTcF) &gt;= 480 msec on
                  screening electrocardiogram (EKG)

               -  Known history of QT/correct QT (QTc) prolongation or Torsades de Pointes (TdP)

               -  ST depression or elevation of &gt;= 1.5 mm in 2 or more leads

               -  Diarrhea of any cause &gt;= Common Terminology Criteria for Adverse Events (CTCAE)
                  grade 2

               -  Active autoimmune disease that is not controlled by nonsteroidal or steroidal (&lt;
                  10 mg of prednisone per day) anti-inflammatory drugs or active inflammatory
                  disease, including small or large intestine inflammation such as active Crohn's
                  disease or ulcerative colitis, which requires immunosuppressive therapy

               -  Psychiatric illness/social situations that would compromise patient safety or
                  limit compliance with study requirements including maintenance of a
                  compliance/pill diary

               -  Known history of chronic liver disease including cirrhosis, current alcohol
                  abuse, or infection with hepatitis B virus or hepatitis C virus (active or
                  carrier) or renal failure

               -  Known history of chronic pancreatitis

               -  Conditions that affect lymphocyte counts, such as human immunodeficiency virus
                  (HIV) infection or immunosuppressive therapy

          -  Use of prohibited drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vandana Abramson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University/Ingram Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama, Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>47405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Breast Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.vicc.org/ct/</url>
    <description>Vanderbilt-Ingram Cancer Center, Find a Clinical Trial</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>May 21, 2015</study_first_submitted>
  <study_first_submitted_qc>May 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2015</study_first_posted>
  <results_first_submitted>February 17, 2020</results_first_submitted>
  <results_first_submitted_qc>April 27, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">May 7, 2020</results_first_posted>
  <last_update_submitted>April 27, 2020</last_update_submitted>
  <last_update_submitted_qc>April 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt-Ingram Cancer Center</investigator_affiliation>
    <investigator_full_name>Vandana Abramson</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 5, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/10/NCT02457910/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>13 enrolled in Phase Ib and 17 in phase II</recruitment_details>
      <pre_assignment_details>13 in phase Ib and 17 in phase II</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>PH1b E+T - Level 1 (Cohort 1)</title>
          <description>Enzalutamide 160 mg PO daily and 2 mg Taselisib PO daily</description>
        </group>
        <group group_id="P2">
          <title>PH1b E+T - Level 2 (Cohort 1 and 2)</title>
          <description>Enzalutamide 160 mg PO daily and Taselisib 4 mg PO daily</description>
        </group>
        <group group_id="P3">
          <title>PH1b E+T - Level 3 (Cohort 1)</title>
          <description>Enzalutamide 160 mg PO daily and Taselisib 6 mg PO daily</description>
        </group>
        <group group_id="P4">
          <title>PH1b E+T - Level 4 (Cohort 1)</title>
          <description>Enzalutamide 160 mg PO daily and Taselisib 8 mg PO daily</description>
        </group>
        <group group_id="P5">
          <title>PHII Enzalutamide</title>
          <description>Enzalutamide 160mg PO daily</description>
        </group>
        <group group_id="P6">
          <title>Phase II E+T</title>
          <description>Enzalutamide 160mg PO daily and Taselisib 4 mg PO daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5">In dose escalation, two patients receiving the 4 mg dose of taselisib were removed for toxicities</participants>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="5">3 participants crossed over to enzalutamide and taselisib</participants>
                <participants group_id="P6" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="11"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Disease progression</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other complicating illness</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>ER/PR+ or TNBC AR+ women with breast cancer</population>
      <group_list>
        <group group_id="B1">
          <title>PH1b E+T - Level 1 (Cohort 1)</title>
          <description>Enzalutamide and Taselisib taken daily by mouth</description>
        </group>
        <group group_id="B2">
          <title>PH1b E+T - Level 2 (Cohort 1 and 2)</title>
          <description>Enzalutamide and Taselisib taken daily by mouth</description>
        </group>
        <group group_id="B3">
          <title>PH1b E+T - Level 3 (Cohort 1)</title>
          <description>Enzalutamide and Taselisib taken daily by mouth</description>
        </group>
        <group group_id="B4">
          <title>PH1b E+T - Level 4 (Cohort 1)</title>
          <description>Enzalutamide and Taselisib taken daily by mouth</description>
        </group>
        <group group_id="B5">
          <title>PHII Enzalutamide</title>
          <description>Enzalutamide taken daily by mouth</description>
        </group>
        <group group_id="B6">
          <title>Phase II E+T</title>
          <description>Enzalutamide and Taselisib taken daily by mouth</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="3"/>
            <count group_id="B4" value="2"/>
            <count group_id="B5" value="5"/>
            <count group_id="B6" value="12"/>
            <count group_id="B7" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="11"/>
                    <measurement group_id="B7" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical Benefit Rate (CBR) - Phase II</title>
        <description>CBR is defined as the proportion of patients with a best response of complete response (CR), partial response (PR), or (SD) stable disease per RECIST criteria 1.1. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt;10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions. PD: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition, the sum must also demonstrate an absolute increase of at least 5 mm. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of diameters while on study. It is calculated as the mean of binomial distribution.</description>
        <time_frame>At 16 weeks</time_frame>
        <population>Evaluable TNBC patients who had at least one cycle of treatment and had their disease re-evaluated at 16 weeks or progressed prior to the 16-week assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I (Taselisib, Enzalutamide)</title>
            <description>Patients receive taselisib PO QD on days 1-28 and enzalutamide PO QD on days 9-28 of course 1 and days 1-28 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing unacceptable toxicity due to enzalutamide may continue to receive taselisib.</description>
          </group>
          <group group_id="O2">
            <title>Arm II (Enzalutamide)</title>
            <description>Patients receive enzalutamide PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Upon disease progression, patients may crossover to Arm I.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Benefit Rate (CBR) - Phase II</title>
          <description>CBR is defined as the proportion of patients with a best response of complete response (CR), partial response (PR), or (SD) stable disease per RECIST criteria 1.1. CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to &lt;10 mm. PR: At least a 30% decrease in the sum of diameters of target lesions. PD: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition, the sum must also demonstrate an absolute increase of at least 5 mm. SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of diameters while on study. It is calculated as the mean of binomial distribution.</description>
          <population>Evaluable TNBC patients who had at least one cycle of treatment and had their disease re-evaluated at 16 weeks or progressed prior to the 16-week assessment</population>
          <units>proportion of patients</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.357" lower_limit="0.163" upper_limit="0.612"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0.434"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Tolerated Dose (MTD) of Taselisib Combined With 160mg Enzalutamide - Phase I</title>
        <description>defined as the highest dose tested in which a dose limiting toxicity is experienced by 0 out of 3 or 1 out of 6 patients among the dose levels. Dose limiting toxicity will be graded according to the National Cancer Institute CTCAE version 4.0.</description>
        <time_frame>4 weeks</time_frame>
        <population>13 patients (7 ER+ and 6 TNBC) breast cancer patients</population>
        <group_list>
          <group group_id="O1">
            <title>2mg Taselisib and 160mg Enzalutamide</title>
            <description>Patients receive 2mg taselisib PO QD on days 1-28 and 160mg enzalutamide PO QD on days 9-28 of course 1 and days 1-28 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing unacceptable toxicity due to enzalutamide may continue to receive taselisib.
160 mg enzalutamide were administered in combination with taselisib starting dose of 2 mg and escalated to 4 mg, 6 mg and 8 mg in a traditional 3+3 trial design.</description>
          </group>
          <group group_id="O2">
            <title>4mg Taselisib and 160mg Enzalutamide</title>
            <description>Patients receive 4mg taselisib PO QD on days 1-28 and 160mg enzalutamide PO QD on days 9-28 of course 1 and days 1-28 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing unacceptable toxicity due to enzalutamide may continue to receive taselisib.</description>
          </group>
          <group group_id="O3">
            <title>6mg Taselisib and 160mg Enzalutamide</title>
            <description>Patients receive 6mg taselisib PO QD on days 1-28 and 160mg enzalutamide PO QD on days 9-28 of course 1 and days 1-28 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing unacceptable toxicity due to enzalutamide may continue to receive taselisib.</description>
          </group>
          <group group_id="O4">
            <title>8mg Taselisib and 160mg Enzalutamide</title>
            <description>Patients receive8mg taselisib PO QD on days 1-28 and 160mg enzalutamide PO QD on days 9-28 of course 1 and days 1-28 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing unacceptable toxicity due to enzalutamide may continue to receive taselisib.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Tolerated Dose (MTD) of Taselisib Combined With 160mg Enzalutamide - Phase I</title>
          <description>defined as the highest dose tested in which a dose limiting toxicity is experienced by 0 out of 3 or 1 out of 6 patients among the dose levels. Dose limiting toxicity will be graded according to the National Cancer Institute CTCAE version 4.0.</description>
          <population>13 patients (7 ER+ and 6 TNBC) breast cancer patients</population>
          <units>DLTs</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Progression-Free Survival (PFS) of Patients Treated With Enzalutamide and Taselisib</title>
        <description>The PFS time is defined as the time from treatment start to progression or death (whichever comes first), and those alive without progression were censored at the last date of follow up. PFS will be estimated using the Kaplan-Meier method. The median with 95% confidence intervals will be reported.</description>
        <time_frame>Time from course 1, day 1 until objective tumor progression, assessed up to 3 years</time_frame>
        <population>Evaluable Androgen Receptor Positive Triple Negative Metastatic Breast Cancer patients that received enzalutamide + taselisib regardless of dose assignment. It is pre-specified by the study protocol to combined groups of TN MBC patients who received both drugs for overall PFS.</population>
        <group_list>
          <group group_id="O1">
            <title>Patients Received Both Enzalutamide and Taselisib</title>
            <description>Patients received enzalutamide and taselisib from phase I and phase II and evaluable</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Progression-Free Survival (PFS) of Patients Treated With Enzalutamide and Taselisib</title>
          <description>The PFS time is defined as the time from treatment start to progression or death (whichever comes first), and those alive without progression were censored at the last date of follow up. PFS will be estimated using the Kaplan-Meier method. The median with 95% confidence intervals will be reported.</description>
          <population>Evaluable Androgen Receptor Positive Triple Negative Metastatic Breast Cancer patients that received enzalutamide + taselisib regardless of dose assignment. It is pre-specified by the study protocol to combined groups of TN MBC patients who received both drugs for overall PFS.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" lower_limit="2.1" upper_limit="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetic Profile</title>
        <description>Pharmacokinetic sampling will occur in the phase Ib portion and in 10 patients in the phase II portion</description>
        <time_frame>Approximately 4 months</time_frame>
        <population>Data was not collected because taselisib is no longer being developed commercially.</population>
        <group_list>
          <group group_id="O1">
            <title>Combination of Taselisib and Enzalutamide</title>
            <description>Patients receive taselisib PO QD on days 1-28 and enzalutamide PO QD on days 9-28 of course 1 and days 1-28 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing unacceptable toxicity due to enzalutamide may continue to receive taselisib.
160 mg enzalutamide were administered in combination with taselisib starting dose of 2 mg and escalated to 4 mg, 6 mg and 8 mg in a traditional 3+3 trial design.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetic Profile</title>
          <description>Pharmacokinetic sampling will occur in the phase Ib portion and in 10 patients in the phase II portion</description>
          <population>Data was not collected because taselisib is no longer being developed commercially.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Approximately 42 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Taselisib 2 mg</title>
          <description>Patients receive taselisib PO QD on days 1-28 and enzalutamide PO QD on days 9-28 of course 1 and days 1-28 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing unacceptable toxicity due to enzalutamide may continue to receive taselisib.</description>
        </group>
        <group group_id="E2">
          <title>Taselisib 4 mg</title>
          <description>Patients receive taselisib PO QD on days 1-28 and enzalutamide PO QD on days 9-28 of course 1 and days 1-28 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing unacceptable toxicity due to enzalutamide may continue to receive taselisib.</description>
        </group>
        <group group_id="E3">
          <title>Taselisib 6 mg</title>
          <description>Patients receive taselisib PO QD on days 1-28 and enzalutamide PO QD on days 9-28 of course 1 and days 1-28 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing unacceptable toxicity due to enzalutamide may continue to receive taselisib.</description>
        </group>
        <group group_id="E4">
          <title>Taselisib 8 mg</title>
          <description>Patients receive taselisib PO QD on days 1-28 and enzalutamide PO QD on days 9-28 of course 1 and days 1-28 of subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients experiencing unacceptable toxicity due to enzalutamide may continue to receive taselisib.</description>
        </group>
        <group group_id="E5">
          <title>Enzalutamide</title>
          <description>Patients receive enzalutamide PO QD on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Upon disease progression, patients may crossover to receive Enzalutamide + Taselisib</description>
        </group>
        <group group_id="E6">
          <title>Enzalutamide + Taselisib</title>
          <description>Patients receive enzalutamide PO QD starting on day 1 of cycle 1, and will receive PO QD Taselisib on day 1 of cycle 2.</description>
        </group>
        <group group_id="E7">
          <title>Cross-Over</title>
          <description>Upon progression of disease, patients on the enzalutamide only arm will be allowed to crossover to enzalutamide + taselisib (must begin no later than 21 days after the clinic visit at which disease progression is determined) Enzalutamide and Taselisib will be taken PO QD</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Heart failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Left ventricular systolic dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms benign</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" events="6" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" events="6" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E7" events="3" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E6" events="7" subjects_affected="7" subjects_at_risk="12"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="9" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="4" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Vomitting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Mucositis oral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="12" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E3" events="6" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E5" events="7" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E6" events="21" subjects_affected="10" subjects_at_risk="12"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" events="10" subjects_affected="6" subjects_at_risk="12"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Limb edema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E6" events="4" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E7" events="3" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Alanine amininotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>White blood cell decreased</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="3" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="15" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" events="5" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hypermagnesemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hypernatremia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="4" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Rash acneiform</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E7" events="3" subjects_affected="2" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Dry Skin</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" events="6" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Vandana Abramson, MD</name_or_title>
      <organization>Vanderbilt University Medical Center</organization>
      <phone>(615)936-8422</phone>
      <email>vandana.abramson@vumc.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

